NewAmsterdam Pharma (NAMS) Set to Release Quarterly Earnings on Wednesday

NewAmsterdam Pharma (NASDAQ:NAMS) is projected to release its Q3 2026 results before the market opens on Wednesday, November 4th. Analysts expect the company to announce earnings of ($0.4949) per share and revenue of $7.54 million for the quarter. Interested persons can check the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 5, 2026 at 9:30 AM ET.

NewAmsterdam Pharma (NASDAQ:NAMS) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.04). The company had revenue of $3.70 million for the quarter, compared to analyst estimates of $2.83 million. On average, analysts expect NewAmsterdam Pharma to post ($1.82) EPS for the current fiscal year and ($1.62) EPS for the next fiscal year.

NewAmsterdam Pharma Stock Up 5.0%

Shares of NAMS opened at $20.50 on Wednesday. The company has a market capitalization of $2.45 billion, a P/E ratio of -9.49 and a beta of 0.10. NewAmsterdam Pharma has a twelve month low of $19.13 and a twelve month high of $42.21. The firm has a 50 day moving average of $23.29 and a 200 day moving average of $30.03.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on NAMS shares. Weiss Ratings restated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a report on Thursday, October 15th. Jefferies Financial Group reissued a “buy” rating and set a $45.00 target price on shares of NewAmsterdam Pharma in a research note on Monday, July 20th. BMO Capital Markets initiated coverage on shares of NewAmsterdam Pharma in a report on Monday, July 20th. They set an “outperform” rating and a $58.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and set a $52.00 target price on shares of NewAmsterdam Pharma in a research report on Tuesday, September 8th. Finally, Royal Bank Of Canada lowered their target price on NewAmsterdam Pharma from $50.00 to $42.00 and set an “outperform” rating for the company in a report on Monday, October 5th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, NewAmsterdam Pharma presently has an average rating of “Moderate Buy” and an average target price of $48.90.

Insider Buying and Selling

In related news, insider Johannes Kastelein sold 125,000 shares of the business’s stock in a transaction on Monday, August 24th. The shares were sold at an average price of $26.91, for a total transaction of $3,363,750.00. Following the completion of the transaction, the insider directly owned 69,302 shares in the company, valued at $1,864,916.82. The trade was a 64.33% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director John W. Smither sold 1,600 shares of the stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $25.32, for a total value of $40,512.00. Following the sale, the director directly owned 8,760 shares in the company, valued at $221,803.20. This represents a 15.44% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 176,846 shares of company stock worth $4,661,919. 12.74% of the stock is owned by company insiders.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma (NASDAQ: NAMS) is a clinical-stage biopharmaceutical company focused on developing therapies for cardiometabolic diseases. The company’s primary investigational product is obicetrapib, an oral, low-dose cholesteryl ester transfer protein (CETP) inhibitor designed to reduce low-density lipoprotein cholesterol and potentially address residual cardiovascular risk in patients who remain inadequately controlled on existing treatments.

NewAmsterdam is evaluating obicetrapib in late-stage clinical studies involving patients with dyslipidemia, including individuals with heterozygous familial hypercholesterolemia and patients who are unable to reach cholesterol goals with currently available therapies.